vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
CROSS COUNTRY HEALTHCARE INC is the larger business by last-quarter revenue ($236.8M vs $185.2M, roughly 1.3× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -35.0%, a 35.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -23.6%). CROSS COUNTRY HEALTHCARE INC produced more free cash flow last quarter ($16.1M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CCRN vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $185.2M |
| Net Profit | $-82.9M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | -30.2% | 8.6% |
| Net Margin | -35.0% | 0.9% |
| Revenue YoY | -23.6% | 23.7% |
| Net Profit YoY | -2109.7% | -88.5% |
| EPS (diluted) | $-2.56 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $185.2M | ||
| Q3 25 | $250.1M | $169.1M | ||
| Q2 25 | $274.1M | $154.7M | ||
| Q1 25 | $293.4M | $125.2M | ||
| Q4 24 | $309.9M | $149.7M | ||
| Q3 24 | $315.1M | $141.5M | ||
| Q2 24 | $339.8M | $126.7M | ||
| Q1 24 | $379.2M | $110.4M |
| Q4 25 | $-82.9M | $1.7M | ||
| Q3 25 | $-4.8M | $17.3M | ||
| Q2 25 | $-6.7M | $-24.4M | ||
| Q1 25 | $-490.0K | $-21.7M | ||
| Q4 24 | $-3.8M | $14.7M | ||
| Q3 24 | $2.6M | $-6.7M | ||
| Q2 24 | $-16.1M | $-15.7M | ||
| Q1 24 | $2.7M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | 20.4% | 88.5% | ||
| Q2 25 | 20.4% | 90.2% | ||
| Q1 25 | 20.0% | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | 20.4% | 90.6% | ||
| Q2 24 | 20.8% | 91.1% | ||
| Q1 24 | 20.4% | 87.7% |
| Q4 25 | -30.2% | 8.6% | ||
| Q3 25 | -2.4% | 20.3% | ||
| Q2 25 | -2.1% | -6.1% | ||
| Q1 25 | -0.3% | -6.3% | ||
| Q4 24 | -1.1% | 10.7% | ||
| Q3 24 | 0.9% | 15.3% | ||
| Q2 24 | -5.7% | 11.8% | ||
| Q1 24 | 0.8% | -25.1% |
| Q4 25 | -35.0% | 0.9% | ||
| Q3 25 | -1.9% | 10.2% | ||
| Q2 25 | -2.4% | -15.8% | ||
| Q1 25 | -0.2% | -17.3% | ||
| Q4 24 | -1.2% | 9.8% | ||
| Q3 24 | 0.8% | -4.8% | ||
| Q2 24 | -4.7% | -12.4% | ||
| Q1 24 | 0.7% | -43.9% |
| Q4 25 | $-2.56 | $0.00 | ||
| Q3 25 | $-0.15 | $0.06 | ||
| Q2 25 | $-0.20 | $-0.08 | ||
| Q1 25 | $-0.02 | $-0.07 | ||
| Q4 24 | $-0.13 | $0.05 | ||
| Q3 24 | $0.08 | $-0.02 | ||
| Q2 24 | $-0.47 | $-0.05 | ||
| Q1 24 | $0.08 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $322.8M | $274.2M |
| Total Assets | $449.0M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $293.5M | ||
| Q3 25 | $99.1M | $263.8M | ||
| Q2 25 | $81.2M | $231.0M | ||
| Q1 25 | $80.7M | $250.6M | ||
| Q4 24 | $81.6M | $249.9M | ||
| Q3 24 | $64.0M | $249.8M | ||
| Q2 24 | $69.6M | $260.1M | ||
| Q1 24 | $5.2M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $322.8M | $274.2M | ||
| Q3 25 | $408.1M | $230.4M | ||
| Q2 25 | $412.2M | $204.3M | ||
| Q1 25 | $418.2M | $193.6M | ||
| Q4 24 | $419.0M | $194.0M | ||
| Q3 24 | $424.7M | $178.8M | ||
| Q2 24 | $433.3M | $132.5M | ||
| Q1 24 | $462.4M | $130.7M |
| Q4 25 | $449.0M | $949.9M | ||
| Q3 25 | $538.2M | $868.8M | ||
| Q2 25 | $553.8M | $815.3M | ||
| Q1 25 | $576.2M | $789.8M | ||
| Q4 24 | $589.3M | $785.0M | ||
| Q3 24 | $597.4M | $786.6M | ||
| Q2 24 | $602.9M | $749.5M | ||
| Q1 24 | $648.4M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $16.3M |
| Free Cash FlowOCF − Capex | $16.1M | $16.0M |
| FCF MarginFCF / Revenue | 6.8% | 8.6% |
| Capex IntensityCapex / Revenue | 0.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $16.3M | ||
| Q3 25 | $20.1M | $35.7M | ||
| Q2 25 | $4.2M | $-26.5M | ||
| Q1 25 | $5.7M | $7.8M | ||
| Q4 24 | $24.2M | $-3.9M | ||
| Q3 24 | $7.5M | $-23.0M | ||
| Q2 24 | $82.4M | $22.7M | ||
| Q1 24 | $6.0M | $-29.7M |
| Q4 25 | $16.1M | $16.0M | ||
| Q3 25 | $17.9M | $35.3M | ||
| Q2 25 | $2.3M | $-28.9M | ||
| Q1 25 | $3.8M | $7.5M | ||
| Q4 24 | $21.7M | $-4.2M | ||
| Q3 24 | $6.3M | $-23.3M | ||
| Q2 24 | $79.6M | $21.6M | ||
| Q1 24 | $3.8M | $-31.5M |
| Q4 25 | 6.8% | 8.6% | ||
| Q3 25 | 7.2% | 20.9% | ||
| Q2 25 | 0.8% | -18.7% | ||
| Q1 25 | 1.3% | 6.0% | ||
| Q4 24 | 7.0% | -2.8% | ||
| Q3 24 | 2.0% | -16.5% | ||
| Q2 24 | 23.4% | 17.0% | ||
| Q1 24 | 1.0% | -28.5% |
| Q4 25 | 0.9% | 0.2% | ||
| Q3 25 | 0.9% | 0.2% | ||
| Q2 25 | 0.7% | 1.6% | ||
| Q1 25 | 0.6% | 0.2% | ||
| Q4 24 | 0.8% | 0.2% | ||
| Q3 24 | 0.4% | 0.3% | ||
| Q2 24 | 0.8% | 0.9% | ||
| Q1 24 | 0.6% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
